flow trial semaglutide kidney outcomes 2024 ADA 24: Trial: in Patients Treated with FLOW trial for semaglutide kidney

Originally developed for diabetes, then approved for obesity, and now showing promise for various psychiatric conditions including binge eating disorder, substance use disorders, and possibly depression itself

[DOI] [PubMed] [Google Scholar] 222

Its really powerful, and its lucrativeand so its going to be used over and over and over again to motivate people. The promise of a quick fix, via a weight loss program, diet, or drug has made many fortunes

Sustained stimulation stabilize -arrestin binding, locking the receptor in an internalized state [70], which promotes receptor ubiquitination, and receptor down-regulation as shown with muscarinic receptor agonists [71]

In addition, cross-sectional dietary analyses suggest that GLP-1RA therapy can reduce nutrient intake in ways that may affect protein and micronutrient sufficiency [75]